Buscar | Applechat

agregó una foto Health

2026-06-17 10:30:00 -

Neuroendocrine Carcinoma Market: How Is Peptide Receptor Radionuclide Therapy Becoming the Fastest-Growing Standard-of-Care Modality?

Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors — the Lutetium-177 DOTATATE (Lutathera) and emerging radioligand therapies targeting somatostatin receptor-positive NETs representing the fastest-expanding treatment category in the global neuroendocrine carcinoma landscape — creates the most clinically transformative market segment, with the Neuroendocrine...

0 Commentarios 0 Acciones 137 Views 0 Vista previa